Platelet adhesion and aggregation receptors

Platelet adhesion and aggregation receptors represent a complex network of cell surface proteins essential for primary hemostasis and the pathological development of arterial thrombosis (StatPearls, 2023). This group includes adhesion receptors like the Glycoprotein Ib-IX-V complex, which binds to von Willebrand factor, and Glycoprotein VI, which interacts with subendothelial collagen (NCBI, 2022). The aggregation process is primarily mediated by the integrin alphaIIb beta3 (GPIIb/IIIa), which undergoes a conformational change to bind fibrinogen and link adjacent platelets (Blood, 2012). Activation receptors, such as the P2Y12 purinergic receptor and Protease-activated receptors (PAR1/4), amplify these responses by sensing ADP and thrombin, respectively (PubMed, 2019). Pharmacological targeting of these receptors is a cornerstone of cardiovascular medicine, utilizing agents like P2Y12 inhibitors and GPIIb/IIIa antagonists to prevent myocardial infarction and stroke. However, the therapeutic window is narrow, as inhibiting these physiological interactions inherently increases the risk of significant bleeding complications (NIH, 2021).

Other names

Platelet surface receptorsThrombocyte adhesion receptorsPlatelet glycoprotein receptorsPlatelet activation receptors

Inhibition of platelet activation and aggregation through various pathways, including P2Y12 receptor antagonism, GPIIb/IIIa receptor blockade, and inhibition of thromboxane A2 synthesis.